Physician profile
Amy Olsen
NPI 1598991275
$1,406.98
in general payments reported to CMS, 2019-2025
22 companies · $560 in 2025
The $560 reported for 2025 was more than what 77% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $26.16 · 2022: $97.81 · 2023: $326 · 2024: $397 · 2025: $560.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,283.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,283.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $422.33 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $180.68 | 2022-2024 | Mounjaro, Emgality, Jardiance |
| Corcept Therapeutics | $117.32 | 2024-2025 | Korlym |
| Amgen INC. | $116.87 | 2024-2025 | Evenity, Prolia, Prolia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $70.48 | 2022-2024 | Jardiance |
| Globus Medical, INC. | $69.61 | 2024 | Rise, Base, Modulus |
| Novo Nordisk INC | $66.09 | 2024-2025 | Ozempic, Rybelsus |
| Organon LLC | $63.52 | 2023-2025 | Nexplanon |
| Merck Sharp & Dohme LLC | $45.12 | 2025 | Verquvo |
| Abbvie INC. | $34.82 | 2024-2025 | |
| Idorsia Pharmaceuticals US INC | $30.15 | 2022-2023 | Quviviq |
| Pfizer INC. | $29.44 | 2023 | |
| Axsome Therapeutics, INC. | $19.97 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.78 | 2025 | |
| Beta Bionics, INC. | $17.25 | 2024 | Ilet Bionic Pancreas |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $16.85 | 2022 | |
| Neurocrine Biosciences, INC. | $16.12 | 2025 | |
| Xeris Pharmaceuticals, INC. | $15.64 | 2023 | Gvoke Hypopen |
| Ardelyx, INC. | $15.46 | 2025 | Ibsrela |
| Boston Scientific Corporation | $15.32 | 2025 | Wavewriter Alpha Prime 16 |
| Tandem Diabetes Care, INC. | $13.24 | 2021 | |
| Medtronic, INC. | $12.92 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Olsen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.